ORIGINAL.



IN THE UNITED STATES OF AMERICA BEFORE THE FEDERAL TRADE COMMISSION OFFICE OF ADMINISTRATIVE LAW JUDGES

In the Matter of DANIEL CHAPTER ONE,) Docket No.: 9329
a corporation, and)
JAMES FEIJO,) PUBLIC DOCUMENT
individually, and as an officer of)
Daniel Chapter One)
)
)
)
)

RESPONDENTS' RESPONSE TO COMPLAINT COUNSEL'S REQUEST FOR ADMISSIONS

As ordered by the Administrative Law Judge's Order of February 11, 2009, Respondents, through their counsel, respond to Complaint Counsel's Request for Admissions. Each request is repeated below, followed by the response.

The address for the Corporate Respondent is 1028 East Main Road, Portsmouth, Rhode
 Island 02871.

RESPONSE: Admit.

2. The Individual Respondent, alone or with others, controls or directs, or has controlled or has directed, the actions of the Corporate Respondent.

RESPONSE: Admit.

3. Patricia Feijo is an officer, director, or manager of the Corporate Respondent.

RESPONSE: Admit.

4. During the time period in which the Challenged Products have been advertised, promoted, or offered for sale, the Individual Respondent has held the position of Overseer of the Corporate Respondent.

RESPONSE: Admit.

 The Individual Respondent's business address is the same as the business address for the Corporate Respondent.

RESPONSE: Admit.

6. The Individual Respondent is responsible for managing the marketing and intellectual property of the Challenged Products.

RESPONSE: Admit that Individual Respondent is responsible for managing the educational and intellectual property of the Challenged Products. Deny that the activities managed by Individual Respondent constitute marketing.

7. The Individual Respondent has supervised persons who have engaged in activities relating to the promotion and/or sale of the Challenged Products.

RESPONSE: Admit that persons supervised by Individual Respondent have engaged in activities relating to providing the Challenged Products to individuals and organizations. Deny that such activities constitute promotion and/or sale of such products.

8. The Individual Respondent has supervised Patricia Feijo's activities relating to the promotion and/or sale of the Challenged Products.

RESPONSE: Admit that Individual Respondent has supervised the Daniel Chapter One activities of Patricia Feijo. Deny that such activities include the promotion and/or sale of products.

9. The Individual Respondent has supervised Dr. Bill Maclean's activities relating to the

promotion and/or sale of the Challenged Products.

RESPONSE: Deny. Dr. Bill Mclean represents a supplier to Daniel Chapter One and Individual Respondent has not supervised any of his activities.

10. Respondents have offered for sale, and received payment for, the Challenged Products to consumers in numerous states of the United States.

RESPONSE: Deny that products are offered for sale. Products are provided for donations which vary in amounts, or are supplied as gifts or charitable contributions.

11. Promotional materials for the Challenged Products have appeared in numerous states of the United States.

RESPONSE: Admit that materials related to the Challenged Products have appeared in many states. Deny that such materials constitute promotional materials.

12. The Individual Respondent approved the promotional materials for the Challenged Products.

RESPONSE: Admit that Individual Respondent approved materials related to the Challenged Products. Deny that such materials constitute promotional materials.

13. During the time period in which the Challenged Products have been advertised and sold, the Individual Respondent has been familiar with the claimed scientific substantiation for the Challenged Products' promotional materials.

RESPONSE: Deny that Challenged Products have been promoted, advertised or sold. Admit that the Individual Respondent has been familiar with the claimed scientific substantiation for the Challenged Products' educational materials.

14. The Respondents provide monetary remuneration to persons who work on their behalf, including, but not limited to, engaging in activities relating to the promotion and sale of

the Challenged Products.

RESPONSE: Deny that Respondents or persons working on their behalf engage in promotion and sale of products. The Respondents *may* provide monetary remuneration for work, but at times have also bartered products for work, and at times people have donated work to Respondents.

15. The Respondents control the content of the Web site <u>www.danielchapterone.com</u>.

RESPONSE: Admit.

16. The Respondents control the content of the Web site www.delpages.com. [sic]

RESPONSE: Deny that Respondents control the content of the Web site www.de1pages.com. Admit that Respondents control the content of the Web site www.dc1pages.com.

17. The Respondents control the content of the Web site www.dcstore.com. [sic]

RESPONSE: Deny that Respondents control the content of the Web site www.dcstore.com. Admit that Respondents control the content of the Web site www.dc1store.com.

18. The Respondents control the content of the Web site www.7HerbFormula.com.

RESPONSE: Admit.

19. The Respondents control the content of the Web site www.gdu2000.com.

RESPONSE: Admit.

20. The Web site <u>www.danielchapterone.com</u> advertises, markets, promotes, or sells the Challenged Products.

RESPONSE: Deny that the Web site <u>www.danielchapterone.com</u> advertises, markets, promotes or sells products.

21. The Web site www.dclpages.com advertises, markets, promotes, or sells the Challenged Products.

RESPONSE: Deny that the Web site www.dclpages.com advertises, markets, promotes or

active or inactive ingredients contained in the Challenged Products.

RESPONSE: Deny. Materials in the possession of Respondents in some cases include or reference the results of clinical trials performed by third parties on the active or inactive ingredients contained in the Challenged Products.

29. Respondents did not conduct any tests on the efficacy of Bio*Shark as a product that prevents, treats, or cures cancer or tumors.

RESPONSE: Admit.

Respondents did not ask any other person or entity to conduct tests on the efficacy of Bio*Shark as a product that prevents, treats, or cures cancer or tumors.

RESPONSE: Admit.

31. Respondents did not conduct any tests on the efficacy of 7 Herb Formula as a product that prevents, treats, or cures cancer or tumors.

RESPONSE: Admit.

32. Respondents did not ask any other person or entity to conduct tests on the efficacy of 7

Herb Formula as a product that prevents, treats, or cures cancer or tumors.

RESPONSE: Admit.

Respondents did not conduct any tests on the efficacy of GDU as a product that prevents, treats, or cures cancer or tumors.

RESPONSE: Admit.

Respondents did not ask any other person or entity to conduct tests on the efficacy of GDU as a product that prevents, treats, or cures cancer or tumors.

RESPONSE: Admit.

27

28

35. Respondents did not conduct any tests on the efficacy of BioMixx as a product that

prevents, treats, or cures cancer or tumors.

RESPONSE: Admit.

36. Respondents did not ask any third parties to conduct tests on the efficacy of BioMixx as a product that prevents, treats, or cures cancer or tumors.

RESPONSE: Admit.

37. Respondents do not possess any scientific evidence that the Challenged Products, taken either individually or collectively, prevent, treat, or cure cancers or tumors.

RESPONSE: Deny.

38. The Challenged Products, taken either individually or collectively, do not prevent, treat or cure cancers or tumors.

RESPONSE: Deny.

39. The Challenged Products are "foods" or "drugs" within the meaning of Sections 12 and 15 of the FTC Act, 15 U.S.C. §§ 55(b) and 55(c).

RESPONSE: Deny. The Challenged Products are dietary supplements.

The Food and Drug Administration (FDA) issued an August 15, 2008 warning letter ("FDA letter") to Respondents, stating that it found that 7 Herb Formula and other products distributed, sold, or promoted by Respondents "to be drugs under section 201(g)(l)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(l)(B)]."

RESPONSE: Admit, and Respondents object to the FDA statement.

41. The Corporate Respondent engages in economic activity that meets the definition of "commerce" in 15 U.S.C. § 44.

RESPONSE: Deny.

42. The Corporate Respondent receives funds from, and in return provides products to, individuals in various parts of the United States.

RESPONSE: Admit that the Corporate Respondent receives funds from, and provides products to, individuals in various parts of the United States. Deny that the products are provided "in return" for the funds to the extent that such statement would imply a sale of the products.

Dated this 23rd day of February, 2009.

Swankin & Turner Attorneys for Respondents

By:

James S. Turner

1400/16th Street, NW, Suite 101

Washington, DC 20036 Ph: 202-462-8800

Fax: 202-265-6564

Email: jim@swankin-turner.com

IN THE UNITED STATES OF AMERICA BEFORE THE FEDERAL TRADE COMMISSION OFFICE OF ADMINISTRATIVE LAW JUDGES

In the Matter of

DANIEL CHAPTER ONE,
a corporation, and

JAMES FEIJO,
individually, and as an officer of
Daniel Chapter One

Docket No.: 9329

PUBLIC DOCUMENT

CERTIFICATE OF SERVICE

I certify that on February 23, 2009, I served or caused to be served the following document on the individuals listed below by electronic mail, followed by Federal Express delivery:

Respondents' Response to Complaint Counsel's Requests for Admissions

18 | Service to:

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

20

22

23

24

25

26

27

¹⁹ | Donald S. Clark

Office of the Secretary

Federal Trade Commission

21 | 600 Pennsylvania Avenue, NW, Room H-135

Washington, DC 20580

Email: secretary@ftc.gov

Leonard L. Gordon, Esq. (lgordon@ftc.gov)

Theodore Zang, Jr., Esq. (tzang@ftc.gov)

Carole A. Paynter, Esq. (cpaynter@ftc.gov)

David W. Dulabon, Esq. (ddulabon@ftc.gov)

Federal Trade Commission – Northeast Region

One Bowling Green, Suite 318

New York, NY 10004

28

Hon. D. Michael Chappell Administrative Law Judge 600 Pennsylvania Avenue, NW, Room H-106

Email: oalj@ftc.gov

Martin R. Yerick Swankin & Turner 1400 16th Street, NW, Suite 101

Washington, DC 20036